Scilex Pharmaceuticals

Developing and commercializing non-opioid approaches to treat pain

Frazier Life Sciences originally invested in Semnur Pharmaceuticals, a specialty pharmaceuticals company advancing novel non-opioid therapeutics for patients with chronic back pain. In 2019, Semnur merged with Scilex, a majority owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE). Scilex’s lead product is ZTlido 1.8%, a lidocaine topical delivery system which has been approved by the U.S. FDA to treat post-herpetic neuralgia. Scilex launched ZTLido in Q4 2018. Scilex is also developing SP-102, a non-opioid corticosteroid gel developed at Semnur, which is currently in Phase 3 pivotal studies for the treatment of lumbar radicular pain/sciatica and which has also been granted Fast Track status from the FDA.

Status
Merger with Semnur Pharmaceuticals in 2018
Year of Investment
2013
Strategy
Life Sciences
Location
Mountain View, California